CIBC Asset Management
MRSN

CIBC Asset Management’s Mersana Therapeutics MRSN Stock Holding History

CIBC Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,067
Closed -$1.96M – 1112
2023
Q1 		$1.96M Sell
19,067
-3,604
-16% -$506K 0.01% 560
2022
Q4 		$3.32M Buy
+22,671
New +$3.83M 0.01% 436
2022
Q2 		– Sell
-42,240
Closed -$4.21M – 1400
2022
Q1 		$4.21M Hold
42,240
– – 0.01% 390
2021
Q4 		$6.57M Sell
42,240
-112
-0.3% -$21.8K 0.02% 333
2021
Q3 		$9.98M Buy
42,352
+12
+0% +$3.51K 0.04% 234
2021
Q2 		$14.4M Buy
42,340
+29,235
+223% +$11.1M 0.06% 183
2021
Q1 		$5.3M Buy
+13,105
New +$6.36M 0.02% 318

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return